My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$SYMC {{ '2015-08-11T21:48:48+0000' | timeago}} • Webcast

$SYMC 1Q16 Call: Non-GAAP operating margin was 27.4%, an increase of 480 BPs YoverY, driven by lower spend as we aligned costs with lower revenue. We will continue to make operational improvements to our business to expand operating margin as we approach longer-term target of 30%. Non-GAAP net income of $275MM resulted in fully diluted EPS of $0.40

User Jacob Bareto {{ '2016-12-05T21:04:55+0000' | timeago}}

Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$

User Amy Lewis {{ '2016-12-05T19:53:36+0000' | timeago}}

Bad for $AAPL. Despite a 3% increase in wearables shipments as per IDC, Apple Watch shipments plunged a whopping 71%. Smartwatches doesn't seem to take the lead nowadays, basic wearables like $FIT appear to be reigning supreme.

User Jacqueline Gallardo {{ '2016-12-05T19:06:29+0000' | timeago}}

$CRM on the pop today.. big bubble.

User Johney Kingston {{ '2016-12-05T17:47:57+0000' | timeago}}

Slumping and down the drain... $HDSN. Flush out your holdings !

User Dawn Martis {{ '2016-12-05T16:59:46+0000' | timeago}}

$KITE I am loving this one... really flying like a kite today :-)

$XRX {{ '2016-12-06T12:06:48+0000' | timeago}} • Announcement

$XRX appointed Joseph Echevarria, the former CEO of Deloitte LLP, and Cheryl Krongard, a former senior partner with Apollo Management LP, to its BoD effective Jan. 1, 2017. With these additions, $XRX Board will comprise 11 directors.

$CELG {{ '2016-12-06T12:03:36+0000' | timeago}} • Announcement

$CELG announced interim results from Abound clinical trial program evaluating use of Abraxane in patients with advanced non-small cell lung cancer (NSCLC). The study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in pivotal Phase 3 trial.

$PM {{ '2016-12-06T12:01:08+0000' | timeago}} • Announcement

$PM submitted on Dec. 5 a modified risk tobacco product (MRTP) application for its electronically heated tobacco product with the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products. $PM expects FDA to take minimum of 60 days to complete administrative review to determine whether to accept application for substantive review.

$JNJ {{ '2016-12-06T11:56:46+0000' | timeago}} • Announcement

Janssen Research & Development, a $JNJ company, said new Ibrutinib (Imbruvica) phase 2 data demonstrate promise in relapsed/refractory marginal zone lymphoma (MZL), a rare incurable type of non-hodgkin's lymphoma. Janssen said half of patients with relapsed/refractory MZL responded to ibrutinib.

$CELG {{ '2016-12-06T11:48:40+0000' | timeago}} • Announcement

$CELG announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) who had received prior hypomethylating agents (HMA).